'Benefit risk' presentation slideshows

869 views • 67 slides

Life Cycle Management Regulatory Issues Alcon, Novartis (Pharmaceuticals & Devices) Dr. Zubair Hussain Head of Regu

692 views • 52 slides

Prof. Jean-Louis TEBOUL Medical ICU Bicetre hospital University Paris XI France

What is the best way to assess fluid responsiveness in a spontaneously breathing patient ?. Prof. Jean-Louis TEBOUL Medical ICU Bicetre hospital University Paris XI France. Member of the Medical Advisory Board of Pulsion . Three different scenarios.

1.17k views • 50 slides

Critical Path Initiative: What it means for pharmaceutical industry statisticians

812 views • 45 slides

Acute Coronary Syndrome #2

Acute Coronary Syndrome #2. July 26, 2013. Class of Recommendation. Level of Evidence. A. Class I: Benefit >>> Risk Class IIa: Benefit >> Risk Class IIb: Benefit ? Risk Class III: Risk ? Benefit. Data from randomized clinical trials or meta-analysis.

753 views • 45 slides

DSMB Experiences

534 views • 38 slides

Opportunities in Pharmaceutical Sales Training

479 views • 31 slides

428 views • 30 slides

400 views • 26 slides

Nat ional Medicines Agencies roles in Pharmacovigilance

432 views • 25 slides

Signal identification and development

Signal identification and development. I.Ralph Edwards. Adverse Reaction Signal. Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously.

395 views • 24 slides

WHAT THE PHARMACEUTICAL RESEARCH ENTERPRISE PROVIDES

Presentation of the Pharmaceutical Research and Manufacturers of America at FDA Part 15 Hearing on Communication of Drug Safety Information December 8, 2005 Alan Goldhammer, PhD Pharmaceutical Research & Manufacturers of America agoldhammer@phrma.org.

398 views • 22 slides

Food & Drug Law Institute Annual Conference Washington, D.C. April 22, 2009

277 views • 20 slides

Unwrapping the Cotton Wool Kids in North Lanarkshire

386 views • 20 slides

MCDA in drug benefit-risk analysis: the case of second-generation antidepressants

MCDA in drug benefit-risk analysis: the case of second-generation antidepressants. T. Tervonen(1), H.L. Hillege(2), D. Postmus(3) 1 Faculty of Economics and Business, RUG.nl 2 Department of Cardiology/Epidemiology, UMCG.nl 3 Department of Epidemiology, UMCG.nl. Regulatory Logic.

489 views • 19 slides

Tedisamil for Conversion of Atrial Fibrillation

Tedisamil for Conversion of Atrial Fibrillation. Thomas A. Marciniak, M.D. Division of Cardiovascular and Renal Products U.S. Food & Drug Administration. Fundamental question:. Not whether tedisamil works, BUT Is the benefit/risk tradeoff favorable enough to justify approval?.

306 views • 18 slides

Artesunate Rectal Capsules

Artesunate Rectal Capsules. For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment is not available

651 views • 15 slides

528 views • 10 slides

Consumer Care

Consumer Care. Bayer Corporation Consumer Care Division September 19, 2002 Allen H. Heller, MD Vice President, Global Research & Development. Bayer OTC Analgesic Products. Acetaminophen Containing - Multi-symptom Combinations Alka-Seltzer ? Plus -- Cough/Cold/Allergy Midol ? -- Menstrual

196 views • 9 slides

Assessment of Risk Benefit

287 views • 8 slides